FLT3 and acute myeloid leukemia: The first such case was reported in conjunction with midostaurin therapy; in that case, the emergence of a single amino acid substitution within the tyrosine kinase domain (N676K) was sufficient to facilitate resistance in a patient with FLT3-ITD AML [150].